-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RNCfuoDv1TGxPispFkOSg6TDw8Ma5hWJywNSwIqODIEtGGeqAdmb5YJdLDtufBno dc57uX/TG4jnzJFrPg/sDA== 0000950109-96-004674.txt : 19960729 0000950109-96-004674.hdr.sgml : 19960729 ACCESSION NUMBER: 0000950109-96-004674 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19960722 ITEM INFORMATION: Other events FILED AS OF DATE: 19960726 SROS: NONE FILER: COMPANY DATA: COMPANY CONFORMED NAME: ROBERTS PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0000853022 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222429994 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10432 FILM NUMBER: 96599495 BUSINESS ADDRESS: STREET 1: MERIDIAN CENTRE II STREET 2: 4 INDUSTRIAL WAY W CITY: EATONTOWN STATE: NJ ZIP: 07724 BUSINESS PHONE: 9083891182 MAIL ADDRESS: STREET 1: MERIDIAN CTR II STREET 2: 4 INDUSTRIAL WAY WEST CITY: EATONTOWN STATE: NJ ZIP: 07724 8-K 1 FORM 8-K FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 1996 Roberts Pharmaceutical Corporation ---------------------------------------------------------- (Exact name of registrant as specified in its charter) New Jersey 1-10432 22-2429994 - ---------------- ---------------- ----------------- (State or other (Commission (IRS Employer jurisdiction File Number Identification of incorporation) Number) Meridian Center II 4 Industrial Way West Eatontown, New Jersey 07724 - -------------------------------------------------------------------------------- (Address of principal executive office, including zip code) Registrant's telephone number, including area code: (908)389-1182 - -------------------------------------------------------------------------------- (Former name or former address, if changed since last report.) Item 5. Other Events ------------ On July 22, 1996, Roberts Pharmaceutical Corporation announced that the Health Protection Branch, Canada has notified it that Eminase(R) the Company's life saving thrombolytic therapy, has been approved for that market. Eminase is a cardiovascular agent which Roberts currently markets in the U.S., U.K., and elsewhere for the treatment of acute myocardial infarction (heart attack). Eminase is indicated for use in the dissolution of thrombi (clots) obstructing coronary arteries; to improve ventricular function and to reduce mortality associated with acute myocardial infarction. Compared with other thrombolytic therapies that require administration by infusion over 60 to 90 minutes or longer, Eminase is administered in minutes by direct injection. Roberts acquired the worldwide rights to Eminase from SmithKline Beecham in 1995 and has since been positioning the product for international market opportunities. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Roberts Pharmaceutical Corporation ---------------------------------- (Registrant) By: /s/ Anthony A. Rascio ------------------------------ Anthony A. Rascio Vice President Date: July 26, 1996 -----END PRIVACY-ENHANCED MESSAGE-----